Seqens Group Opens Flagship Pharmaceutical R&D Center in Boston

The Seqens group has announced today that it has opened a state-of-the-art, 1,500 sqm R&D center in Devens, Mass., to serve as one of the company’s global center of excellence, bringing customers advanced capabilities for the discovery and development of new drugs and therapeutics.

The $5 million investment ensures that the new facility will leverage the most advanced technologies, equipment and design, while adhering to the highest levels of quality, sustainability and safety. With more than 20 world-class scientists, the new Devens lab serves as the North American flagship for Seqens’ global R&D network –consisting of 10 R&D centers across Europe and North America and 300-plus scientists leveraging best-in-class technologies to support pharmaceutical customers from preclinical phases through to commercialization.
The facility replaces an older, smaller R&D lab in Devens; all current employees are shifting to the new facility
The investment in Devens significantly strengthens the company’s U.S. operations —which also includes contract development and manufacturing facilities in nearby Newburyport, Mass. —and signals Seqens’ commitment to broadening its reach into the U.S. The official opening comes just a year after SK Capital became a majority shareholder in the group by merging it with its portfolio company Wavelength Pharmaceuticals to create one of the largest, most diversified CDMOs in the world.
“Transitioning our R&D center of excellence to the new Devens facility is an opportunity to support our growing expansion into the U.S. market and to support our customers with integrated R&D services that set new benchmarks for innovation, safety, sustainability and quality, said Pierre Luzeau, president and CEO of Seqens.
In addition to the re-development of its Devens lab, Seqens is investing significantly across the company to support customers’ growth in both its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high potency APIs, and biocatalysts. Seqens is also committed to the highest levels of environmental, social and governance standards, with 15 EcoVadis platinum and gold sites among its global integrated network, which comprises 24 manufacturing sites, 10 R&D centers, more than 300 scientists and 3,400 employees located on 3 continents.